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Abstract
Malignant tumors of the nasal cavity are rare. We report the case of a 48 years old man who consulted us with a
2-year history of progressive nasal obstruction, occasional epistaxis, facial pain, and watering of the eyes. A
diagnosis of olfactory neuroblastoma was established by histopathology and confirmed by immunohistochemistry.
On staging, the mass was classified as a Kadish stage C tumor with extensive involvement of the nasal cavities,
nasopharynx, paranasal sinuses and orbit. Endoscopic excision of the mass was done. Traditionally the mainstay of
treatment in such locally advanced patients is craniofacial resection followed by adjuvant radiotherapy. Our patient
was treated with limited surgery and chemoradiation. Patient is free of recurrence at a follow-up of 5 years. This
case report demonstrates the potential efficacy of planned combined modality therapy, including limited surgery
and early chemoradiation in the control of locally advanced olfactory neuroblastoma.
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Background
Malignant tumors of the nasal cavity are rare. Olfactory
neuroblastomas also known as esthesioneuroblastomas
(ENB) is a rare and aggressive malignant tumor account-
ing for only 6% of nasal cavity and paranasal sinus neo-
plasms and 0.3% of the upper aero digestive tract
malignancies [1]. Treatment recommendations range from
a minimally invasive approach to combined modality
treatment including craniofacial resection and chemo
radiotherapy [2].
Case Presentation
In June 2004, a 48 year old male presented with pro-
gressive bilateral nasal obstruction, and bleeding
through nostrils since 3 years associated with facial pain
and blurred left eye vision from 6 months.
Computed tomography dated- June 2004 (figure 1)
showed large mass involving both nasal cavities, parana-
sal sinuses, nasopharynx, left pterygoid plates, left ptery-
gopalatine fossa, hard palate, and orbit. There was no
clinically or radiologically evident disease in neck, chest
or abdomen. An endoscopically guided biopsy disclosed
esthesioneuroblastoma.
Histopathology section showed an infiltrating round
cell tumor with areas of necrosis and hemorrhage, partly
ulcerating the overlying nasopharyngeal mature epithe-
lium. Tumour cells showed nuclear molding with occa-
sional rosettes (figure 2a and 2b).
Immunohistochemistry profile (figure 2c and 2d)
showed positivity for neural marker namely neuron spe-
cific enolase. The tumor cells were negative for epithelial
markers cytokeratin and epithelial membrane antigen
( f i g u r e2 ea n d2 f )H e n c ead i a g n o s i so fa d u l te s t h e s i o -
neuroblastoma of nasal cavity was made.
P a t i e n tw a sp l a n n e df o ru p f r o n tc h e m o t h e r a p yf o l -
lowed by radiotherapy in June 2004. Surgical excision in
form of craniofacial surgical resection was not done due
to non-availability of technical advances and surgical
expertise. Patient received 6 cycles of cisplatin (20 mg/m
2
day1-5), etoposide (100 mg/m
2 day1-5) and bleomycin
(30 mg day2, 9 and 16) at 3 weekly interval, followed by
external beam radiotherapy. Radiotherapy was planned
with one anterior and two lateral wedge pair fields with
unequal weighting and treatment was delivered via Tele-
cobalt Unit Theratron 780C ( AECL, Ottawa, Canada)
with dose normalized at tumor center. Dose homogeneity
requirement was 95-105% of the specified centrally
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any medium, provided the original work is properly cited.Figure 1 Pre-treatment axial and coronal paranasal sinuses and orbit contrast-enhanced CT-Scan (a, b). Showing bulky soft-tissue mass
in left maxilla, bilateral ethmoid sinuses, nasal cavity, pterygopalatine fossa, nasopharynx with destruction of medial and lateral wall of orbit.
Figure 2 Microphotograph showing small cells with rosettes (H & E × 125 × digital magnification) (a, b) neuron specific enolase
positive in tumor cells(c, d), Cytokeratin and epithelial membrane antigen negative in tumor (DAB × 125 × digital magnification) (e, f).
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point. Two-dimensional computer planning was done on
Radplan software (TSG Corporation, India). Patient
received total dose of 56Gy in 28 fractions in 5 1/2 weeks.
Post radiation patient had significant improvement in
symptoms but CT-Scan revealed residual disease (figure
3), therefore 4 more cycles of cisplatin (20 mg/m
2 day1-5)
and etoposide (100 mg/m
2 day1-5) chemotherapy was
given at 3 weekly interval. Treatment was completed in
June 2005; subsequently our patient has been clinically
asymptomatic through out the follow up period of 5 yrs.
The latest C.T scan done in June 2010 (figure 4)showed
evidence of post radiation changes most likely to be fibro-
sis in left maxillary antrum with marked new bone forma-
tion and no sign of disease.
Discussion
Extension of primary tumor based on the Kadish staging
system has been identified as the most important deter-
minant of the treatment outcome [3,4].
Figure 3 Axial and coronal contrast-enhanced paranasal sinuses and orbit CT-scan after 6 cycles of chemotherapy and radiotherapy
(a, b). showing marked reduction in the tumor, the lesion is limited to the left maxillary sinus. A partial tumor remission was considered.
Figure 4 Axial and coronal contrast-enhanced paranasal sinuses and orbit computed tomography scan after completion of treatment
(a, b). The scan is showing post radiation changes most likely to be fibrosis.
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ease Kadish stage C without intracranial extension was
treated with limited surgery combined with chemora-
diotherapy which has shown good response and disease
free survival of 5 years. Presently our patient is clinically
and radiologically free of disease.
Craniofacial surgery is the mainstay of treatment in
ENB regardless of stage and grade with the possible
exception of distance metastasis followed by adjuvant
radiation in high grade and locally advanced tumors. [5].
In unresectable ENB the experience with chemoradia-
tion is lacking and is under-reported probably due to
limited cases, but some of the latest series have shown
promising results in nonsurgical approach [2].
Encouraged by these results we treated our patient
who had locally advanced disease by limited surgery due
to non-availability of technical advances and surgical
expertise followed by chemo radiation, with excellent
clinical outcome.
Conclusion
Chemoradiation along with limited surgery can be con-
sidered as one of the treatment modalility for locally
advanced ENB with promising results.
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